Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A. is dated April 8, 2026. The report serves as a vehicle to distribute a press release (Exhibit 99.1) to U.S. investors. The registrant is a foreign private issuer based in Marseille, France, and files annual reports on Form 20-F.
Key Financial Metrics
The provided filing text contains only the cover page and signature block of the Form 6-K. It does not include the content of the referenced press release or any financial statements. Consequently, the filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material changes versus prior periods can be identified from the provided text, as no comparative financial data or operational updates are included in the cover document.
Guidance, Outlook, and Risks
The filing references a press release dated April 8, 2026, but the text of that release is not included in the input. Therefore, no guidance, management commentary, risks, contingencies, or unusual items can be summarized from the available source data.
Investor Verification Checklist
- Verify the content of the referenced Press Release (Exhibit 99.1) to understand the specific event triggering this filing.
- Confirm whether the press release contains updated clinical trial data, partnership announcements, or financial guidance.
- Review the company's most recent Form 20-F or quarterly reports for the latest audited financial metrics, as this 6-K does not contain them.